Trial Search Results
Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumors
The purpose of this study is to assess the median progression-free survival (PFS)of patients with well differentiated, metastatic and/or unresectable typical or atypical lung neuroendocrine tumors treated with Lanreotide Autogel/Depot plus BSC versus placebo plus BSC.
Stanford is currently not accepting patients for this trial.